6446 — PHARMAESSENTIA Balance Sheet
0.000.00%
Last trade - 00:00
- TWD231.94bn
- TWD212.93bn
- TWD5.11bn
- 33
- 2
- 100
- 39
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,396 | 3,212 | 3,454 | 11,280 | 19,688 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 200 | 451 | 493 | 840 | 1,548 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,919 | 4,147 | 4,927 | 13,375 | 22,896 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 757 | 903 | 780 | 1,045 | 2,836 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 2,959 | 5,531 | 6,198 | 15,333 | 27,269 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 337 | 1,087 | 1,412 | 2,550 | 2,152 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 704 | 1,611 | 1,948 | 3,191 | 3,321 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 2,255 | 3,920 | 4,250 | 12,141 | 23,948 |
Total Liabilities & Shareholders' Equity | 2,959 | 5,531 | 6,198 | 15,333 | 27,269 |
Total Common Shares Outstanding |